ABSTRACTSystemic lupus erythmatosus (SLE) is an autoimmune disease which involved many organs. One of its severe manifestations is lupus nephritis (LN). Treatment of LN consist of two phases, induction and maintenance. Inappropriate treatmen approach could increase morbidity and mortality in LN pantients. Renal flare is among many bad outcomes of LN that should be mitigated with an approciate therapuitec approach. Various guidelines stated usage of mycophenolate mofetil (MMF) or azathioprine (AZA) as an appropriate immunosuppresant in the maintenence phase